-
BY
EDIT Stock Jumps on EDIT-401 CRISPR Data: Is Editas Medicine Becoming an In Vivo Gene Editing Comeback Play?
Key Takeaways Editas Medicine (NASDAQ: EDIT) moved sharply higher as investors focused on the company’s EDIT-401 program, recent preclinical data, and renewed interest in CRISPR gene editing stocks. EDIT-401 is Editas Medicine’s lead in vivo gene editing candidate for hyperlipidemia and atherosclerotic cardiovascular disease risk reduction. The company reported strong non-human primate data showing roughly…
Latest Posts
-
EDIT Stock Jumps on EDIT-401 CRISPR Data: Is Editas Medicine Becoming an In Vivo Gene Editing Comeback Play?
Key Takeaways Editas Medicine (NASDAQ: EDIT) moved sharply higher as investors…
BY
-
RIVN Stock Jumps After Rivian Raises 2026 Delivery Guidance: Is the R2 SUV the Next Growth Catalyst?
Key Takeaways RIVN stock moved sharply higher after Rivian reported stronger-than-expected…
BY
-
SOC Stock Surge: Financing Overhang Relief or High-Risk Energy Rebound?
Key Takeaways Sable Offshore (SOC) surged after the company priced a…
BY
-
DLO Stock Surge: dLocal Revalued as an Emerging Market Payments Growth Stock?
Key Takeaways dLocal (DLO) surged as investors reacted to strong Q1…
BY
-
AVAV Stock Surge: Drone Defense Earnings Surprise or BlueHalo Revaluation?
Key Takeaways AeroVironment (AVAV) surged after the company reported a major…
BY
-
IRDM Stock Surge: Rocket Lab Acquisition Premium or Satellite Infrastructure Revaluation?
Key Takeaways Iridium Communications (IRDM) surged after Rocket Lab announced a…
BY